<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput xmlns:ns2="local" id="94872" name="RGX-121"><HDS>Phase 2 Clinical</HDS><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><Actions><Action id="23534" type="primary">IDS gene stimulator</Action><Action id="4781" type="secondary">Adeno-associated virus based gene therapy</Action></Actions><Indications><Indication id="2254" type="primary">Hunter syndrome</Indication></Indications><Entities><Entity>Biological</Entity></Entities><OriginatorCompany id="1054635">REGENXBIO Inc</OriginatorCompany></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyDrugSummaryOutput>